Preferred Label : glucagon-like peptides;

MeSH definition : Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.;

MeSH synonym : glucagon like polypeptides; glucagon-like polypeptides; Glucagon Like Peptides; Glucagon-Like Polypeptide; Glucagon Like Polypeptide; Polypeptide, Glucagon-Like; Glucagon-Like Peptide; Glucagon Like Peptide; Peptide, Glucagon-Like;

MeSH hyponym : enteroglucagons; Enteroglucagon; Gut Glucagon; Glucagon, Gut;

Registry Number MeSH : 62340-29-8;

Wikipedia link : https://en.wikipedia.org/wiki/Enteroglucagons;

Is substance : O;

Details


Main resources

You can consult :

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

https://www.usherbrooke.ca/baladocritique/archives/episode-40-etude-step1/
2021
Canada
sound
safety
persons
obesity, nos
semaglutide
obesity
Obesity
data collection
Ketoacidosis
episode of
Obesity
obesity
Safety
glucagon-like peptides

---
https://www.has-sante.fr/jcms/p_3282761/fr/rybelsus-7-14-mg-semaglutide
2021
false
false
false
France
evaluation of the transparency committee
Product containing precisely semaglutide 3 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely semaglutide 7 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely semaglutide 14 milligram/1 each conventional release oral tablet (clinical drug)
diabetes mellitus, type 2
hypoglycemic agents
semaglutide
Glucagon-Like Peptide-1 Receptor
semaglutide
glucagon-like peptides
treatment outcome
insurance, health, reimbursement
administration, oral

---
https://www.cbip.be/fr/articles/3625?folia=3622
2021
false
false
false
Belgium
French
journal article
drug information
administration, oral
semaglutide
GLP-1 Mimetics
diabetes mellitus, type 2
pharmaceutic aids
salcaprozate sodium
treatment outcome
Product containing precisely semaglutide 7 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely semaglutide 14 milligram/1 each conventional release oral tablet (clinical drug)
semaglutide
body weight
hypoglycemic agents
hypoglycemic agents
semaglutide
N-(8-(2-hydroxybenzoyl)amino)caprylate
glucagon-like peptides
glucagon-like peptides
caprylates

---
https://www.has-sante.fr/jcms/p_3225392/fr/trulicity
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
injections, subcutaneous
hypoglycemic agents
adult
drug therapy, combination
Product containing only dulaglutide (medicinal product)
evaluation of the transparency committee
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins

---
https://www.has-sante.fr/jcms/p_3225389/fr/rybelsus
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
semaglutide
semaglutide
semaglutide
Glucagon-like peptide 1 receptor agonist (disposition)
Glucagon-Like Peptide-1 Receptor
administration, oral
diabetes mellitus, type 2
evaluation of the transparency committee
glucagon-like peptides
glucagon-like peptides

---
https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
semaglutide
semaglutide
semaglutide
diabetes mellitus, type 2
adult
administration, oral
Product containing only semaglutide in oral dose form (medicinal product form)
Glucagon-Like Peptide-1 Receptor
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
glucagon-like peptides
glucagon-like peptides

---
https://www.usherbrooke.ca/baladocritique/archives/episode-26-etude-rewind/
2019
false
false
false
false
Canada
immunoglobulin fc fragments
glucagon-like peptides
recombinant fusion proteins
cardiovascular diseases
treatment outcome
hypoglycemic agents
Glucagon-Like Peptide-1 Receptor
sound
diabetes mellitus, type 2
dulaglutide

---
https://www.has-sante.fr/portail/jcms/c_2906429/fr/ozempic
https://www.has-sante.fr/portail/jcms/c_2906429/fr/ozempic-semaglutide-antidiabetique
2019
false
false
false
France
treatment outcome
semaglutide
semaglutide
semaglutide
injections, subcutaneous
insurance, health, reimbursement
adult
diabetes mellitus, type 2
drug therapy, combination
guidelines for drug use
metformin
insulin
sulfonylurea compounds
evaluation of the transparency committee
glucagon-like peptides
glucagon-like peptides

---
https://www.has-sante.fr/jcms/c_2906429/fr/ozempic
2019
false
false
false
France
semaglutide
semaglutide
semaglutide
diabetes mellitus, type 2
drug therapy, combination
metformin
Glucagon-Like Peptide-1 Receptor
adult
injections, subcutaneous
treatment outcome
hypoglycemic agents
sulfonylurea compounds
evaluation of the transparency committee
glucagon-like peptides
glucagon-like peptides

---
https://www.ema.europa.eu/medicines/human/EPAR/Ozempic
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
semaglutide
semaglutide
drug approval
europe
treatment outcome
adult
diabetes mellitus, type 2
injections, subcutaneous
Pre-filled Pen Syringe
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin
cardiovascular diseases
diabetes complications
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
semaglutide
glucagon-like peptides
glucagon-like peptides

---
https://www.revmed.ch/RMS/2017/RMS-N-565/Association-des-analogues-du-GLP-1-et-des-inhibiteurs-du-SGLT2-de-nouvelles-perspectives
2018
false
false
false
Switzerland
French
journal article
administration, oral
hypoglycemic agents
diabetes mellitus, type 2
switzerland
treatment outcome
body weight
cardiovascular diseases
drug therapy, combination
GLP-1 Mimetics
glucagon-like peptide 1
Glucagon-like peptide-1 (GLP-1) analogues
SGLT2 Inhibitor
Sodium-Glucose transporter 2
dulaglutide
Liraglutide
empagliflozin
dapagliflozin
Canagliflozin
blood glucose
arterial pressure
genetic pleiotropy
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
peptides
venoms
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
benzhydryl compounds
glucosides
Exenatide

---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
diabetes mellitus, type 2
review of literature
consensus
GLP-1 Mimetics
treatment outcome
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
metformin
hypoglycemic agents
hypoglycemic agents
glimepiride
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
sulfonylurea compounds
comparative effectiveness research
arterial pressure
insulin
thyroid neoplasms
pancreatitis
Injection Site Reaction
cardiovascular diseases
practice guidelines as topic
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
peptides
venoms
peptides
venoms
thiazolidinediones
Pioglitazone
Exenatide
Exenatide

---
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity
http://www.has-sante.fr/portail/jcms/c_2036398/fr/trulicity-dulaglutide-antidiabetique
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
drug therapy, combination
insulins
dulaglutide
dulaglutide
hypoglycemic agents
hypoglycemic agents
glucagon-like peptide 1
diabetes mellitus, type 2
metformin
adult
injections, subcutaneous
dulaglutide
dulaglutide
dulaglutide
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides

---
http://www.medecinesciences.org/index.php?option=com_article&access=standard&Itemid=129&url=/articles/medsci/pdf/2003/07/medsci2003198-9p860.pdf
http://dx.doi.org/10.1051/medsci/20031989860
2003
false
France
French
Insulin Secretion
diabetes mellitus
incretins
glucagon-like peptides
journal article

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.